Vir Biotechnology disclosed new data showing its combination regimen for chronic hepatitis D keeps viral levels low and supports an accelerated Phase 3 program, presented at AASLD. Company statements at the meeting indicate pivotal trials are advancing ahead of schedule based on the strength of the viral‑suppression signal. The results matter because chronic hepatitis D has few effective treatments; a monthly regimen that sustains viral control could address an unmet need and expand Vir’s infectious‑disease franchise if Phase 3 confirms clinical benefit beyond surrogate virology endpoints.